Facilitating Innovative Nuclear Diagnostics Act of 2023
USA118th CongressHR-1199| House
| Updated: 5/16/2024
Neal P. Dunn
Republican Representative
Florida
Cosponsors (47)
Adrian Smith (Republican)Chris Pappas (Democratic)Guy Reschenthaler (Republican)Robin L. Kelly (Democratic)Lisa Blunt Rochester (Democratic)Gregory F. Murphy (Republican)Darren Soto (Democratic)Claudia Tenney (Republican)Mariannette Miller-Meeks (Republican)Terri A. Sewell (Democratic)Eric Swalwell (Democratic)Tony Cárdenas (Democratic)Jennifer Wexton (Democratic)Scott H. Peters (Democratic)Paul Tonko (Democratic)Angie Craig (Democratic)Donald M. Payne (Democratic)Earl L. "Buddy" Carter (Republican)Frank J. Mrvan (Democratic)Jake Auchincloss (Democratic)Ted Lieu (Democratic)Rudy Yakym (Republican)Ann M. Kuster (Democratic)
Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Facilitating Innovative Nuclear Diagnostics Act of 2023 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2024 and as adjusted based on a specified fee schedule factor in each year thereafter.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Forwarded by Subcommittee to Full Committee by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Health
Health care costs and insuranceMedical tests and diagnostic methodsMedicareRadiation
Facilitating Innovative Nuclear Diagnostics Act of 2023
USA118th CongressHR-1199| House
| Updated: 5/16/2024
Facilitating Innovative Nuclear Diagnostics Act of 2023 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2024 and as adjusted based on a specified fee schedule factor in each year thereafter.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Forwarded by Subcommittee to Full Committee by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Neal P. Dunn
Republican Representative
Florida